VYNE Therapeutics Inc. - Common Stock

VYNE Therapeutics Inc. - Common Stock

Share · US92941V3087 · VYNE (XNAS)
Overview
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of VYNE Therapeutics Inc. - Common Stock
Analyst Grade Summary
gauge-img
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell
0
1
1
0
0
No Price
28.04.2026 20:00
Current Prices from VYNE Therapeutics Inc. - Common Stock
ExchangeTickerCurrencyLast TradePriceDaily Change
XNAS: NASDAQ
NASDAQ
VYNE
USD
28.04.2026 20:00
0,64 USD
0,001 USD
+0,22 %
IEXG: IEX
IEX
VYNE
USD
28.04.2026 19:26
0,64 USD
0,004 USD
+0,60 %
Share Float & Liquidity
Free Float 81,75 %
Shares Float 13,62 M
Shares Outstanding 16,66 M
Company Profile for VYNE Therapeutics Inc. - Common Stock Share
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

Company Data

Name VYNE Therapeutics Inc. - Common Stock
Company VYNE Therapeutics Inc.
Symbol VYNE
Website https://www.vynetherapeutics.com
Primary Exchange XNAS NASDAQ
ISIN US92941V3087
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO David T. Domzalski
Market Capitalization 11 Mio
Country United States of America
Currency USD
Employees 0,0 T
Address 520 U.S. Highway 22, 08807 Bridgewater
IPO Date 2018-01-25

Stock Splits

Date Split
13.02.2023 1:18
16.02.2021 1:4

ID Changes

Date From To
08.09.2020 MNLO VYNE

Ticker Symbols

Name Symbol
NASDAQ VYNE
More Shares
Investors who hold VYNE Therapeutics Inc. - Common Stock also have the following shares in their portfolio:
BNY Mellon Diversified Emerging Markets Fund
BNY Mellon Diversified Emerging Markets Fund Fund
The Sage Group plc
The Sage Group plc Depository Receipt